skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2]; ;  [3];  [2];  [4]
  1. Baoji Maternal and Child Health Hospital, 2 Xinjian Road East, WeiBin District, Baoji City, 721000, Shanxi Province (China)
  2. Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China)
  3. Kyoto University, Kyoto 606-8507 (Japan)
  4. Baoji Hospital of Traditional Chinese Medicine, No 43, BaoFu Road, Baoji City, Shanxi Province (China)

Highlights: • Established CRISPR/Cas9 targeting promoter of HPV 16 and targeting E6, E7 transcript. • CRISPR/Cas9 resulted in accumulation of p53 and p21, reduced the proliferation of cervical cancer cells. • Finding inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9. • CRISPR/Cas9 will be a new treatment strategy, in cervical and other HPV-associated cancer therapy. - Abstract: Deregulated expression of high-risk human papillomavirus oncogenes (E6 and E7) is a pivotal event for pathogenesis and progression in cervical cancer. Both viral oncogenes are therefore regarded as ideal therapeutic targets. In the hope of developing a gene-specific therapy for HPV-related cancer, we established CRISPR/Cas9 targeting promoter of HPV 16 E6/E7 and targeting E6, E7 transcript, transduced the CRISPR/Cas9 into cervical HPV-16-positive cell line SiHa. The results showed that CRISPR/Cas9 targeting promoter, as well as targeting E6 and E7 resulted in accumulation of p53 and p21 protein, and consequently remarkably reduced the abilities of proliferation of cervical cancer cells in vitro. Then we inoculated subcutaneously cells into nude mice to establish the transplanted tumor animal models, and found dramatically inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9 targeting (promoter+E6+E7)-transcript. Our results may provide evidence for application of CRISPR/Cas9 targeting HR-HPV key oncogenes, as a new treatment strategy, in cervical and other HPV-associated cancer therapy.

OSTI ID:
22416689
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 450, Issue 4; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells
Journal Article · Fri Sep 05 00:00:00 EDT 2014 · Biochemical and Biophysical Research Communications · OSTI ID:22416689

MAML1 regulates cell viability via the NF-{kappa}B pathway in cervical cancer cell lines
Journal Article · Mon Aug 01 00:00:00 EDT 2011 · Experimental Cell Research · OSTI ID:22416689

Papillomavirus E6 proteins
Journal Article · Fri Feb 20 00:00:00 EST 2009 · Virology · OSTI ID:22416689